[
{"Name" : "DM ORZ GMENU DIABETES MANAGEMENT (UPDATE 7/2023)", "Term" : "Edited 7/21/23 - update to VA/DoD guidelines To me, it seems that without comorbidities and with comorbidities could be the same for the first three agents (metformin, SGLT-2, GLP-1).  This is an opportunity to simplify the menu without needing to separate by the presence of comorbidities.  After that TZD (avoid in CHF and bladder cancer), or DPP-4 (alternative to GLP-1).  Then SFU and insulin.  MTB- CACEDITED 06/28/2023 - Given update to VA/DoD guidelines, needed to shift SGLT2i up on the menu. Also shifted some 3rd line agents around due to cost/guideline recommendations. New order will be: 2nd line SGLT2i, 3rd line SFU, DPP4i, then TZD Wyatt Gold, Pharmacy Informatics Created 8/3/22 per LEAF request #173 for Type 2 Diabetes Management Menu from Shane Crook.  MTB-CAC", "DisplayText" : "Diabetes Type II Management... ", "Version" : "DM", "Contents" : [
{"Row" : 1, "Column" : 1, "Text" : "TYPE 2 DIABETES MELLITUS", "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Text" : "FIRST LINE:", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Metformin", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : " Contraindicated if GFR <30"}, 
{"Row" : 15, "Column" : 1, "Item" : "DM PSOZ METFORMIN 500MG DAILY (DM MENU)", "DisplayText" : "METFORMIN 500MG DAILY", "Text" : "   Metformin 500mg Daily (Initiation for Stable CKD w/ GFR 30-45)"},
{"Row" : 16, "Column" : 1, "Item" : "DM PSOZ METFORMIN 1000MG BID (DM MENU)", "DisplayText" : "METFORMIN 500MG BID", "Text" : "   Metformin 500mg BID (MDD if GFR 30-45)"},
{"Row" : 17, "Column" : 1, "Item" : "DM PSOZ METFORMIN 1000MG BID (DM MENU)", "DisplayText" : "METFORMIN 1000MG BID", "Text" : "   Metformin 1000mg BID"},
{"Row" : 19, "Column" : 1, "Text" : "Documented inability to tolerate IR formulation on lowest dose or unable"}, 
{"Row" : 20, "Column" : 1, "Text" : "     to titrate to maximal dose due to ADR:"}, 
{"Row" : 22, "Column" : 1, "Item" : "DM PSOZ METFORMIN 500MG SA DAILY (DM MENU)", "DisplayText" : "METFORMIN 500MG SA DAILY", "Text" : "   Metformin 500mg SA Daily (Initiation for Stable CKD w GFR 30-45)"},
{"Row" : 23, "Column" : 1, "Item" : "DM PSOZ METFORMIN 500MG SA BID (DM MENU)", "DisplayText" : "METFORMIN 500MG SA BID", "Text" : "   Metformin 500mg SA BID (MDD if GFR 30-45)"},
{"Row" : 24, "Column" : 1, "Item" : "DM PSOZ METFORMIN 1000MG SA BID (DM MENU)", "DisplayText" : "METFORMIN 1000MG SA BID", "Text" : "   Metformin 1000mg SA BID"},
{"Row" : 9, "Column" : 2, "Text" : "SECOND LINE:", "Header" : 1}, 
{"Row" : 20, "Column" : 3, "Text" : "TZD (Thiazolidinediones)", "Header" : 1}, 
{"Row" : 21, "Column" : 3, "Text" : "Pioglitazone (Weight (+), A1c dec. (-0.5 to -1.4))"}, 
{"Row" : 23, "Column" : 3, "Text" : "         Less likely to cause hypoglycemia"}, 
{"Row" : 27, "Column" : 3, "Item" : "DM PSOZ PIOGLITAZONE__MG DA", "DisplayText" : "PIOGLITAZONE ____MG DAILY", "Text" : "   Pioglitazone"},
{"Row" : 11, "Column" : 3, "Text" :  "         DPP-4 (Dipeptidyl Peptidase-4 Inhibitors)", "Header" : 1}, 
{"Row" : 12, "Column" : 3, "Text" : "Alogliptin, Saxagliptin, Sitagliptin, linagliptin (Weight (N),"}, 
{"Row" : 13, "Column" : 3, "Text" : "     A1c dec.  (-0.6 to -0.8))"}, 
{"Row" : 14, "Column" : 3, "Text" : "Do NOT Combine with GLP-1 agents"}, 
{"Row" : 17, "Column" : 3, "Item" : "DM PSOZ ALOGLIPTIN __MG DAILY (DM MENU)", "DisplayText" : "ALOGLIPTIN __MG DAILY", "Text" : "   Alogliptin"},
{"Row" : 11, "Column" : 2, "Text" : "         SGLT-2 (Sodium Glucose Co-Transporter 2)", "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Text" : "Empagliflozin, Canagliflozin, Dapagliflozin (Weight (-), A1c dec (-0.5 to -1.0))"}, 
{"Row" : 13, "Column" : 2, "Text" : "Contraindicated: Dialysis, pregnant/nursing, DM-1, high risk for ketoacidosis,"}, 
{"Row" : 14, "Column" : 2, "Text" : "    Hx of (pancreatic surgery, pancreatitis, or alcohol abuse)"}, 
{"Row" : 16, "Column" : 2, "Text" : "            Increased risk of UTIs"}, 
{"Row" : 19, "Column" : 2, "Text" : "Reduced efficacy with eGFR <45"}, 
{"Row" : 17, "Column" : 2, "Text" : "        Benefits in ASCVD, CHF, and CKD"}, 
{"Row" : 21, "Column" : 2, "Item" : "DM PSOZ EMPAGLIFLOZIN 12.5MG DAILY (DM MENU)", "DisplayText" : "EMPAGLIFLOZIN 12.5MG DAILY", "Text" : "   Empagliflozin 12.5mg Daily"},
{"Row" : 9, "Column" : 3, "Text" : "THIRD LINE:", "Header" : 1}, 
{"Row" : 33, "Column" : 2, "Text" : "Increased risk of Diabetes Retinopathy (recommend increased"}, 
{"Row" : 34, "Column" : 2, "Text" : "    monitoring/screening)"}, 
{"Row" : 37, "Column" : 2, "Item" : "DM PSOZ SEMAGLUTIDE TITRATION (0.25MG/0.5MG) WEEKLY X 8W", "DisplayText" : "SEMAGLUTIDE TITRATION (0.25MG/0.5MG) WEEKLY X 8W", "Text" : "   Semaglutide Initial Titration (0.25mg weekly x 4wks, 0.5mg weekly x 4wks)"},
{"Row" : 38, "Column" : 2, "Item" : "DM PSOZ SEMAGLUTIDE (0.5MG) WEEKLY (DM MENU)", "DisplayText" : "SEMAGLUTIDE (0.5MG) WEEKLY", "Text" : "   Semaglutide Maintenance (0.5mg Weekly)"},
{"Row" : 39, "Column" : 2, "Item" : "DM PSOZ SEMAGLUTIDE (1MG) WEEKLY (DM MENU)", "DisplayText" : "SEMAGLUTIDE (1MG) WEEKLY", "Text" : "   Semaglutide Maintenance (1mg Weekly)"},
{"Row" : 31, "Column" : 3, "Text" : "ALTERNATIVE AGENTS (more likely to cause hypoglycemia):", "Header" : 1}, 
{"Row" : 34, "Column" : 3, "Text" : "SFU (Sulfonylureas)", "Header" : 1}, 
{"Row" : 35, "Column" : 3, "Text" : "Glipizide, Glimepiride, Glyburide (Weight (+), A1c dec. (-1.5))"}, 
{"Row" : 36, "Column" : 3, "Text" : "Do NOT use in patient with Sulfa Allergies"}, 
{"Row" : 38, "Column" : 3, "Item" : "DM PSOZ GLIPIZIDE __MG BID", "DisplayText" : "GLIPIZIDE __MG BID", "Text" : "   Glipizide (preferred agent for CKD, MDD = 20mg/Day)"},
{"Row" : 42, "Column" : 3, "Item" : "DM PSOZ GLIMEPERIDE __MG DA", "DisplayText" : "GLIMEPERIDE __MG DAILY", "Text" : "   Glimepiride"},
{"Row" : 40, "Column" : 3, "Text" : "Documented inability to tolerate Glipizide at lowest dose and does not have CKD"}, 
{"Row" : 56, "Column" : 3, "Item" : "DM ORZ GMENU INSULIN TREATMENT MENU", "DisplayText" : "Insulin Treatment Menu", "Text" : "Insulin Treatment Menu...  (Click Here)"},
{"Row" : 25, "Column" : 2, "Item" : "DM PSOZ EMPAGLIFLOZIN/METFORMIN IR COMBO BID (DM MENU)", "DisplayText" : "EMPAGLIFLOZIN/METFORMIN COMBO BID", "Text" : "   Empagliflozin/Metformin IR (Immediate Release) BID"},
{"Row" : 26, "Column" : 2, "Item" : "DM PSOZ EMPAGLIFLOZIN/METFORMIN SA COMBO DAILY (DM MENU)", "DisplayText" : "EMPAGLIFLOZIN/METFORMIN SA COMBO DAILY", "Text" : "   Empagliflozin/Metformin SA (Long Acting) Daily"},
{"Row" : 23, "Column" : 2, "Text" : "         (PREFERRED if in combination with metformin)"}, 
{"Row" : 30, "Column" : 1, "Text" : "Hypoglycemic Treatment Agents", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : "DM PSOZ GLUCOSE TABLETS (DM MENU)", "DisplayText" : "GLUCOSE TABLETS", "Text" : "Glucose Tablets"},
{"Row" : 32, "Column" : 1, "Item" : "DM PSOZ GLUCOSE GEL (DM MENU)", "DisplayText" : "GLUCOSE GEL", "Text" : "Glucose Gel"},
{"Row" : 33, "Column" : 1, "Item" : "DM PSOZ GLUCAGON EMERGENCY KIT (DM MENU)", "DisplayText" : "GLUCAGON EMERGENCY KIT", "Text" : "Glucagon Emergency Kit"},
{"Row" : 35, "Column" : 1, "Text" : "Other:", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : "DM ORZ GMENU DM SUPPLIES (TEMP)", "DisplayText" : "Diabetic Supplies", "Text" : "Diabetic Supplies Menu..."},
{"Row" : 37, "Column" : 1, "Item" : "DM GMRCZ DIABETIC NURSE INSTRUCTION", "DisplayText" : "DIABETIC NURSE INSTRUCTION CONSULT OUTPT", "Text" : "Diabetic Nurse Instruction Consult"},
{"Row" : 38, "Column" : 1, "Item" : "CHF GMRCZ HOME TELEHEALTH ENROLLMENT OUTPT", "DisplayText" : "CCHT/HOME TELEHEALTH", "Text" : "Home Telehealth Consult"},
{"Row" : 39, "Column" : 1, "Item" : "CHF GMRCTZ WEIGHT MANAGEMENT OUTPATIENT CONSULT", "DisplayText" : "WEIGHT MANAGMENT OUTPATIENT CONSULT", "Text" : "Weight Management Consult Menu..."},
{"Row" : 40, "Column" : 1, "Item" : "DM GMRCZ NUTRITION DIABETES EDUCATION CONSULT OUTPATIENT", "DisplayText" : "NUTRITION DIABETES EDUCATION CONSULT OUTPATIENT", "Text" : "Nutritional Diabetes Consult"},
{"Row" : 35, "Column" : 2, "Text" : "Women should discontinue at least 2 months before planned pregnancy"}, 
{"Row" : 2, "Column" : 1, "Text" : "Use high glycemic variability (A1C fluctuation or fasting blood glucose) as a"}, 
{"Row" : 3, "Column" : 1, "Text" : " prognostic indicator for risk of hypoglycemia, morbidity, and mortality"}, 
{"Row" : 4, "Column" : 1, "Text" : "Select A1c Target Range based on risk-benefit ratio, patient characteristics/"}, 
{"Row" : 5, "Column" : 1, "Text" : " preference, complications/comorbidities/life expentancy (A1C range of 7-8.5%"}, 
{"Row" : 6, "Column" : 1, "Text" : " for most patients, when it can be safely obtained)"}, 
{"Row" : 12, "Column" : 1, "Text" : "(Weight (N), A1c dec. (-1.5))"}, 
{"Row" : 18, "Column" : 2, "Text" : "Preferred for HFpEF or HFmrEF"}, 
{"Row" : 22, "Column" : 3, "Text" : "         AVOID in CHF and active Bladder Cancer patients"}, 
{"Row" : 24, "Column" : 3, "Text" : "         May be helpful with NASH"}, 
{"Row" : 25, "Column" : 3, "Text" : "                       Baseline LFTs (Required)"}, 
{"Row" : 32, "Column" : 3, "Text" : "--Prioritize other classes of agents first, especially >= 65 yo"}, 
{"Row" : 32, "Column" : 2, "Text" : "Benefits in ASCVD, CKD (reduced albuminuria)"}, 
{"Row" : 31, "Column" : 2, "Text" : "Slows gastric emptying"}, 
{"Row" : 30, "Column" : 2, "Text" : "Semaglutide, Dulaglutide, Liraglutide (Weight (-), A1c dec. (-0.5 to -1.0))"}, 
{"Row" : 29, "Column" : 2, "Text" : "GLP-1 (Glucagon-like Peptide-1)", "Header" : 1}, 
{"Row" : 45, "Column" : 3, "Text" : "Insulin Treatment", "Header" : 1}, 
{"Row" : 46, "Column" : 3, "Text" : "Insulin Therapy (Weight (+), A1c dec.  (-1.5 to -2.5)"}, 
{"Row" : 15, "Column" : 3, "Text" : "Avoid if high risk of pancreatitis"}, 
{"Row" : 15, "Column" : 2, "Text" : "            Preferred 2nd line per PBM"}, 
{"Row" : 47, "Column" : 3, "Text" : "Consider starting temporarily for new presentations of diabetes WITH GLUCOSE"}, 
{"Row" : 48, "Column" : 3, "Text" : "    TOXICITY (BGs>300, A1C>10, or polyuria/polydipsia/weight loss). Once glucose"}, 
{"Row" : 49, "Column" : 3, "Text" : "    toxicity resolves, simplify and switch to preferred non-insulin agents"}, 
{"Row" : 50, "Column" : 3, "Text" : "    when possible."}, 
{"Row" : 51, "Column" : 3, "Text" : "Preferred in pregnancy"}, 
{"Row" : 52, "Column" : 3, "Text" : "If significant variability or not achieving glycemic goals while on insulin"}, 
{"Row" : 53, "Column" : 3, "Text" : "    therapy, use real-time continuous glucose monitoring to decrease hyopglycemia"}, 
{"Row" : 54, "Column" : 3, "Text" : "    and improve HgA1C."}
]},
{"Name" : "DM ORZ GMENU DM SUPPLIES (TEMP)", "Term" : "TEMPORARY MENU 9/16/2022 - to be inactivated once content in ORZ GMENU DM SUPPLIES is finalized and approved. Wyatt Gold, Pharmacy Informatics", "DisplayText" : "Diabetic Supplies  ", "Version" : "DM", "Contents" : [
{"Row" : 1, "Column" : 1, "Text" : "TESTING", "Header" : 1}, 
{"Row" : 1, "Column" : 2, "Text" : "METERS", "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : "DM ORZ GMENU PHARM GLUCOSE TEST STRIPS", "DisplayText" : "GLUCOSE TEST STRIPS", "Text" : "Glucose Test Strips"},
{"Row" : 4, "Column" : 1, "Item" : "DM PSOZ LANCETS (DM MENU)", "DisplayText" : "LANCETS", "Text" : "Lancets"},
{"Row" : 2, "Column" : 1, "Text" : "****************************************", "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Text" : "ADMINISTRATION", "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Text" : "****************************************", "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Text" : "****************************************", "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : "DM PSOZ INSULIN,SYRINGES (DM MENU)", "DisplayText" : "INSULIN,SYRINGES", "Text" : "Insulin Syringes"},
{"Row" : 11, "Column" : 1, "Item" : "DM PSOZ INSULIN,PEN NEEDLES (DM MENU)", "DisplayText" : "INSULIN,PEN NEEDLES", "Text" : "Pen Needles"},
{"Row" : 12, "Column" : 1, "Item" : "DM PSOZ ALCOCHOL PADS (DM MENU)", "DisplayText" : "ALCOHOL PADS", "Text" : "Alcohol Pads"},
{"Row" : 8, "Column" : 2, "Text" : "PROSTHETICS", "Header" : 1}, 
{"Row" : 9, "Column" : 2, "Text" : "****************************************", "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : "DM GMRCTZ PROSTHETICS REQUEST - DIABETICS SOCKS", "DisplayText" : "PROSTHETICS REQUEST - DIABETICS SOCKS", "Text" : "Diabetic Socks"},
{"Row" : 11, "Column" : 2, "Item" : "GMRCTZ BRACE SPLINT COMP", "DisplayText" : "BRACE/SPLINT/SLEEVE/COMPRESSION-FITTING", "Text" : "BRACE/SPLINT/SLEEVE/COMPRESSION-FITTING"},
{"Row" : 3, "Column" : 2, "Text" : "First Line Device:", "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : "DM GMRCTZ FREESTYLE LITE GLUCOMETER", "DisplayText" : "Freestyle Lite Glucometer-Initial Request Only", "Text" : "Freestyle Lite Glucometer-Initial meter request only"},
{"Row" : 5, "Column" : 2, "Item" : "DM GMRCZ DIABETIC NURSE INSTRUCTION", "DisplayText" : "DIABETIC NURSE INSTRUCTION CONSULT OUTPT", "Text" : "Glucometer - Consult for education/meter training +/- meter"}
]},
{"Name" : "DM ORZ GMENU INSULIN TREATMENT MENU", "DisplayText" : "Insulin Treatment Menu", "Version" : "DM", "Contents" : [
{"Row" : 2, "Column" : 1, "Text" : "LONG-ACTING INSULINS", "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : "DM ORZ SET GLARGINE VIAL WITH SYRINGE", "DisplayText" : "Insulin, Glargine", "Text" : "Insulin, Glargine"},
{"Row" : 15, "Column" : 1, "Item" : "DM ORZ SET GLARGINE PEN WITH PEN NEEDLE", "DisplayText" : "Insulin, Glargine", "Text" : "Insulin, Glargine"},
{"Row" : 13, "Column" : 1, "Text" : "Pen Devices:", "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Text" : "    Management by specialized diabetes provider, documented insulin resistance"}, 
{"Row" : 24, "Column" : 1, "Text" : "     (requires >1 unit/kg/day) and noted hypoglycemia on glargine/detemir despite"}, 
{"Row" : 25, "Column" : 1, "Text" : "     adjustments to regimen"}, 
{"Row" : 28, "Column" : 1, "Item" : "DM ORZ SET TOUJEO PEN WITH PEN NEEDLE", "Text" : "Insulin, Glargine 300unit/ml (Toujeo) 1.5 mL pen"},
{"Row" : 32, "Column" : 1, "Text" : "FAST ACTING INSULINS", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : "DM ORZ SET INSULIN REG VIAL WITH SYRINGE", "Text" : "Insulin, Regular (Novolin R)"},
{"Row" : 38, "Column" : 1, "Item" : "DM ORZ SET INSULIN ASPART VIAL WITH SYRINGE", "Text" : "Insulin, Aspart (Novolog)"},
{"Row" : 41, "Column" : 1, "Text" : "Pen Devices:", "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : "DM ORZ SET NOVOLOG FLEXPEN WITH PEN NEEDLE", "Text" : "Insulin, Aspart (Novolog)"},
{"Row" : 24, "Column" : 2, "Text" : "Unable to tolerate or continues to have hypoglycemia on Glargine 300 unit/ml"}, 
{"Row" : 25, "Column" : 2, "Text" : "    (Toujeo) despite adjustments to current regimen or wide swings in blood sugar"}, 
{"Row" : 26, "Column" : 2, "Text" : "    due to inablity to adhere to basil insulin regimen because of uncontrollable"}, 
{"Row" : 27, "Column" : 2, "Text" : "    variables (i.e. work shifts, dialysis, erratic schedules, etc.)"}, 
{"Row" : 34, "Column" : 2, "Text" : "INTERMEDIATE ACTING INSULINS", "Header" : 1}, 
{"Row" : 30, "Column" : 2, "Item" : "DM ORZ SET TRESIBA PEN WITH PEN NEEDLE", "Text" : "Insulin, Degludec 200 unit/ml (Tresiba)"},
{"Row" : 43, "Column" : 2, "Text" : "Pen Devices:", "Header" : 1}, 
{"Row" : 38, "Column" : 2, "Item" : "DM ORZ SET INSULIN NPH VIAL WITH SYRINGE", "Text" : "Insulin, NPH (Novolin N)"},
{"Row" : 40, "Column" : 2, "Item" : "DM ORZ SET INSULIN NPH/REG VIAL WITH SYRINGE", "Text" : "Insulin, NPH/Regular (Novolin 70/30)"},
{"Row" : 45, "Column" : 2, "Item" : "DM ORZ SET NPH/ASPART 70/30 FLEXPEN WITH PEN NEEDLE", "Text" : "Insulin, NPH/Aspart (Novolog 70/30)"},
{"Row" : 4, "Column" : 1, "Text" : "Vials:", "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Text" : "Vials:", "Header" : 1}, 
{"Row" : 36, "Column" : 2, "Text" : "Vials:", "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Text" : "     Documented inability to tolerate Insulin, Glargine or Determined Insulin,"}, 
{"Row" : 9, "Column" : 1, "Text" : "      Glargine was Clinically ineffective in controlling blood glucose."}, 
{"Row" : 17, "Column" : 1, "Text" : "     Documented inability to tolerate Insulin, Glargine or Determined Insulin,"}, 
{"Row" : 18, "Column" : 1, "Text" : "      Glargine was Clinically ineffective in controlling blood glucose."}, 
{"Row" : 29, "Column" : 1, "Item" : "DM ORZ SET TOUJEO MAX PEN WITH PEN NEEDLE", "Text" : "Insulin, Glargine 300unit/ml (Toujeo Max) 3mL pen"},
{"Row" : 29, "Column" : 2, "Item" : "DM ORZ SET TRESIBA PEN 100UNIT/ML WITH PEN NEEDLE", "DisplayText" : "Insulin, Degludec 100 unit/ml (Tresiba)"},
{"Row" : 11, "Column" : 1, "Text" : "Insulin, Detemir (Convert to Glargine - Removal from market 1/2024)"}, 
{"Row" : 20, "Column" : 1, "Text" : "Insulin, Detemir (Convert to Glargine - Removal from market 1/2024)"}
]},
{"Name" : "DM ORZ GMENU MOVE CONSULTS", "DisplayText" : "Weight Management Consults Menu", "Version" : "DM", "Contents" : [
{"Row" : 1, "Column" : 1, "Text" : "MOVE PROGRAM CONSULTS:", "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : "DM GMRCTZ WEIGHT MANAGEMENT OUTPATIENT CONSULT", "DisplayText" : "WEIGHT MANAGMENT OUTPATIENT CONSULT", "Text" : "WEIGHT MANAGEMENT OUTPATIENT CONSULT (ASHEVILLE VAMC)"},
{"Row" : 5, "Column" : 1, "Item" : "DM GMRCTZ FCBOC WEIGHT MANAGEMENT VTEL OUTPATIENT CONSULT", "DisplayText" : "FCBOC WEIGHT MANAGEMENT VTEL OUTPATIENT CONSULT", "Text" : "WEIGHT MANAGEMENT VTEL OUTPATIENT CONSULT (FRANKLIN CBOC)"}, 
{"Row" : 9, "Column" : 1, "Item" : "DM GMRCTZ RCBOC WEIGHT MANAGEMENT VTEL OUTPATIENT CONSULT", "DisplayText" : "RCBOC WEIGHT MANAGEMENT VTEL OUTPATIENT CONSULT", "Text" : "WEIGHT MANAGEMENT VTEL OUTPATIENT CONSULT (RUTHERFORD CBOC)"},
{"Row" : 7, "Column" : 1, "Item" : "DM GMRCTZ HKYCBOC WEIGHT MANAGEMENT OUTPATIENT CONSULT", "DisplayText" : "HKYCBOC WEIGHT MANAGEMENT OUTPATIENT CONSULT", "Text" : "WEIGHT MANAGEMENT OUTPATIENT CONSULT (HICKORY CBOC)"}
]},
{"Name" : "DM ORZ GMENU PHARM GLUCOSE TEST STRIPS", "Term" : "8/9/2011 At the request of Shane Crook, Clinical Pharmacist and approval of Ken Strum (menu path added) - This menu path has a series of questions designed to walk the provider to the appropriate order.  All menus associated start with ORZ PHARM GLUCOSE Some menus state IDDM or NIDDM - IDDM stands for Insulin Dependent Diabetes Mellitus NIDDM stands for Non-Isulin Dependent Diabetes Mellitus. A. Fortner, CAC", "DisplayText" : "GLUCOSE TEST STRIPS", "Version" : "DM", "Contents" : [
{"Row" : 2, "Column" : 1, "Text" : "The prescribing of BG test strips outside of these aforementioned"}, 
{"Row" : 3, "Column" : 1, "Text" : "restrictions will be handled through the nonforumulary/restricted"}, 
{"Row" : 4, "Column" : 1, "Text" : "consult process with the provision of adequate clinical/medical"}, 
{"Row" : 5, "Column" : 1, "Text" : "justification."}, 
{"Row" : 7, "Column" : 1, "Text" : "If patients' request additional BG test strips which do not coincide"}, 
{"Row" : 8, "Column" : 1, "Text" : "with the guidelines nor is there unique clinical/medical justification"}, 
{"Row" : 9, "Column" : 1, "Text" : "supporting an increase in BG glucose testing the patient may be offered"}, 
{"Row" : 10, "Column" : 1, "Text" : "additional strips to be filled outside of the VA at the veteran's own"}, 
{"Row" : 11, "Column" : 1, "Text" : "personal expense."}, 
{"Row" : 13, "Column" : 1, "Text" : "Type 2 diabetics (Not receiving insulin)"}, 
{"Row" : 14, "Column" : 1, "Item" : "DM ORZ PHARM GLUCOSE TEST STRIPS NIDDM", "DisplayText" : "NIDDM GLUCOSE TEST STRIPS", "Text" : "NIDDM (Non Insulin Dependent Diabetes Mellitus)...", "Mnemonic" : "10"},
{"Row" : 16, "Column" : 1, "Text" : "Type 1 and 2 diabetics (Receiving insulin)"}, 
{"Row" : 17, "Column" : 1, "Item" : "DM ORZ PHARM GLUCOSE TEST STRIPS IDDM", "DisplayText" : "IDDM GLUCOSE TEST STRIPS MENU", "Text" : "IDDM (Insulin Dependent Diabetes Mellitus)...", "Mnemonic" : "20"}
]},
{"Name" : "DM ORZ GMENU DIABETES MANAGEMENT (UPDATE 7/2023)", "Term" : "Edited 7/21/23 - update to VA/DoD guidelines To me, it seems that without comorbidities and with comorbidities could be the same for the first three agents (metformin, SGLT-2, GLP-1).  This is an opportunity to simplify the menu without needing to separate by the presence of comorbidities.  After that TZD (avoid in CHF and bladder cancer), or DPP-4 (alternative to GLP-1).  Then SFU and insulin.  MTB- CACEDITED 06/28/2023 - Given update to VA/DoD guidelines, needed to shift SGLT2i up on the menu. Also shifted some 3rd line agents around due to cost/guideline recommendations. New order will be: 2nd line SGLT2i, 3rd line SFU, DPP4i, then TZD Wyatt Gold, Pharmacy Informatics Created 8/3/22 per LEAF request #173 for Type 2 Diabetes Management Menu from Shane Crook.  MTB-CAC", "DisplayText" : "Diabetes Type II Management... ", "Version" : "DM", "Contents" : [
{"Row" : 1, "Column" : 1, "Text" : "TYPE 2 DIABETES MELLITUS", "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Text" : "FIRST LINE:", "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Text" : "Metformin", "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Text" : "Contraindicated if GFR <30"}, 
{"Row" : 15, "Column" : 1, "Item" : "DM PSOZ METFORMIN 500MG DAILY (DM MENU)", "DisplayText" : "METFORMIN 500MG DAILY", "Text" : "   Metformin 500mg Daily (Initiation for Stable CKD w/ GFR 30-45)"},
{"Row" : 16, "Column" : 1, "Item" : "DM PSOZ METFORMIN 1000MG BID (DM MENU)", "DisplayText" : "METFORMIN 500MG BID", "Text" : "   Metformin 500mg BID (MDD if GFR 30-45)"},
{"Row" : 17, "Column" : 1, "Item" : "DM PSOZ METFORMIN 1000MG BID (DM MENU)", "DisplayText" : "METFORMIN 1000MG BID", "Text" : "   Metformin 1000mg BID"},
{"Row" : 19, "Column" : 1, "Text" : "Documented inability to tolerate IR formulation on lowest dose or unable"}, 
{"Row" : 20, "Column" : 1, "Text" : "     to titrate to maximal dose due to ADR:"}, 
{"Row" : 22, "Column" : 1, "Item" : "DM PSOZ METFORMIN 500MG SA DAILY (DM MENU)", "DisplayText" : "METFORMIN 500MG SA DAILY", "Text" : "   Metformin 500mg SA Daily (Initiation for Stable CKD w GFR 30-45)"},
{"Row" : 23, "Column" : 1, "Item" : "DM PSOZ METFORMIN 500MG SA BID (DM MENU)", "DisplayText" : "METFORMIN 500MG SA BID", "Text" : "   Metformin 500mg SA BID (MDD if GFR 30-45)"},
{"Row" : 24, "Column" : 1, "Item" : "DM PSOZ METFORMIN 1000MG SA BID (DM MENU)", "DisplayText" : "METFORMIN 1000MG SA BID", "Text" : "   Metformin 1000mg SA BID"},
{"Row" : 9, "Column" : 2, "Text" : "SECOND LINE:", "Header" : 1}, 
{"Row" : 20, "Column" : 3, "Text" : "TZD (Thiazolidinediones)", "Header" : 1}, 
{"Row" : 21, "Column" : 3, "Text" : "Pioglitazone (Weight (+), A1c dec. (-0.5 to -1.4))"}, 
{"Row" : 23, "Column" : 3, "Text" : "         Less likely to cause hypoglycemia"}, 
{"Row" : 27, "Column" : 3, "Item" : "DM PSOZ PIOGLITAZONE__MG DA", "DisplayText" : "PIOGLITAZONE ____MG DAILY", "Text" : "   Pioglitazone"},
{"Row" : 11, "Column" : 3, "Text" : "         DPP-4 (Dipeptidyl Peptidase-4 Inhibitors)", "Header" : 1}, 
{"Row" : 12, "Column" : 3, "Text" : "Alogliptin, Saxagliptin, Sitagliptin, linagliptin (Weight (N),"}, 
{"Row" : 13, "Column" : 3, "Text" : "     A1c dec.  (-0.6 to -0.8))"}, 
{"Row" : 14, "Column" : 3, "Text" : "Do NOT Combine with GLP-1 agents"}, 
{"Row" : 17, "Column" : 3, "Item" : "DM PSOZ ALOGLIPTIN __MG DAILY (DM MENU)", "DisplayText" : "ALOGLIPTIN __MG DAILY", "Text" : "Alogliptin"},
{"Row" : 11, "Column" : 2, "Text" : "SGLT-2 (Sodium Glucose Co-Transporter 2)", "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Text" : "Empagliflozin, Canagliflozin, Dapagliflozin (Weight (-), A1c dec (-0.5 to -1.0))"}, 
{"Row" : 13, "Column" : 2, "Text" : "Contraindicated: Dialysis, pregnant/nursing, DM-1, high risk for ketoacidosis,"}, 
{"Row" : 14, "Column" : 2, "Text" : "    Hx of (pancreatic surgery, pancreatitis, or alcohol abuse)"}, 
{"Row" : 16, "Column" : 2, "Text" : "           Increased risk of UTIs"}, 
{"Row" : 19, "Column" : 2, "Text" : "Reduced efficacy with eGFR <45"}, 
{"Row" : 17, "Column" : 2, "Text" : "    Benefits in ASCVD, CHF, and CKD"}, 
{"Row" : 21, "Column" : 2, "Item" : "DM PSOZ EMPAGLIFLOZIN 12.5MG DAILY (DM MENU)", "DisplayText" : "EMPAGLIFLOZIN 12.5MG DAILY", "Text" : "Empagliflozin 12.5mg Daily"},
{"Row" : 9, "Column" : 3, "Text" : "THIRD LINE:", "Header" : 1}, 
{"Row" : 33, "Column" : 2, "Text" : "Increased risk of Diabetes Retinopathy (recommend increased"}, 
{"Row" : 34, "Column" : 2, "Text" : "    monitoring/screening)"}, 
{"Row" : 37, "Column" : 2, "Item" : "DM PSOZ SEMAGLUTIDE TITRATION (0.25MG/0.5MG) WEEKLY X 8W", "DisplayText" : "SEMAGLUTIDE TITRATION (0.25MG/0.5MG) WEEKLY X 8W", "Text" : "   Semaglutide Initial Titration (0.25mg weekly x 4wks, 0.5mg weekly x 4wks)"},
{"Row" : 38, "Column" : 2, "Item" : "DM PSOZ SEMAGLUTIDE (0.5MG) WEEKLY (DM MENU)", "DisplayText" : "SEMAGLUTIDE (0.5MG) WEEKLY", "Text" : "   Semaglutide Maintenance (0.5mg Weekly)"},
{"Row" : 39, "Column" : 2, "Item" : "DM PSOZ SEMAGLUTIDE (1MG) WEEKLY (DM MENU)", "DisplayText" : "SEMAGLUTIDE (1MG) WEEKLY", "Text" : "   Semaglutide Maintenance (1mg Weekly)"},
{"Row" : 31, "Column" : 3, "Text" : "ALTERNATIVE AGENTS (more likely to cause hypoglycemia):", "Header" : 1}, 
{"Row" : 34, "Column" : 3, "Text" : "SFU (Sulfonylureas)", "Header" : 1}, 
{"Row" : 35, "Column" : 3, "Text" : "Glipizide, Glimepiride, Glyburide (Weight (+), A1c dec. (-1.5))"}, 
{"Row" : 36, "Column" : 3, "Text" : "Do NOT use in patient with Sulfa Allergies"}, 
{"Row" : 38, "Column" : 3, "Item" : "DM PSOZ GLIPIZIDE __MG BID", "DisplayText" : "GLIPIZIDE __MG BID", "Text" : "   Glipizide (preferred agent for CKD, MDD = 20mg/Day)"},
{"Row" : 42, "Column" : 3, "Item" : "DM PSOZ GLIMEPERIDE __MG DA", "DisplayText" : "GLIMEPERIDE __MG DAILY", "Text" : "Glimepiride"},
{"Row" : 40, "Column" : 3, "Text" : "Documented inability to tolerate Glipizide at lowest dose and does not have CKD"}, 
{"Row" : 56, "Column" : 3, "Item" : "DM ORZ GMENU INSULIN TREATMENT MENU", "DisplayText" : "Insulin Treatment Menu", "Text" : "Insulin Treatment Menu...  (Click Here)"},
{"Row" : 25, "Column" : 2, "Item" : "DM PSOZ EMPAGLIFLOZIN/METFORMIN IR COMBO BID (DM MENU)", "DisplayText" : "EMPAGLIFLOZIN/METFORMIN COMBO BID", "Text" : "   Empagliflozin/Metformin IR (Immediate Release) BID"},
{"Row" : 26, "Column" : 2, "Item" : "DM PSOZ EMPAGLIFLOZIN/METFORMIN SA COMBO DAILY (DM MENU)", "DisplayText" : "EMPAGLIFLOZIN/METFORMIN SA COMBO DAILY", "Text" : "   Empagliflozin/Metformin SA (Long Acting) Daily"},
{"Row" : 23, "Column" : 2, "Text" : "(PREFERRED if in combination with metformin)"}, 
{"Row" : 30, "Column" : 1, "Text" : "Hypoglycemic Treatment Agents", "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : "DM PSOZ GLUCOSE TABLETS (DM MENU)", "DisplayText" : "GLUCOSE TABLETS", "Text" : "Glucose Tablets"},
{"Row" : 32, "Column" : 1, "Item" : "DM PSOZ GLUCOSE GEL (DM MENU)", "DisplayText" : "GLUCOSE GEL", "Text" : "Glucose Gel"},
{"Row" : 33, "Column" : 1, "Item" : "DM PSOZ GLUCAGON EMERGENCY KIT (DM MENU)", "DisplayText" : "GLUCAGON EMERGENCY KIT", "Text" : "Glucagon Emergency Kit"},
{"Row" : 35, "Column" : 1, "Text" : "Other:", "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : "DM ORZ GMENU DM SUPPLIES (TEMP)", "DisplayText" : "Diabetic Supplies", "Text" : "Diabetic Supplies Menu..."},
{"Row" : 37, "Column" : 1, "Item" : "DM GMRCZ DIABETIC NURSE INSTRUCTION", "DisplayText" : "DIABETIC NURSE INSTRUCTION CONSULT OUTPT", "Text" : "Diabetic Nurse Instruction Consult"},
{"Row" : 38, "Column" : 1, "Item" : "CHF GMRCZ HOME TELEHEALTH ENROLLMENT OUTPT", "DisplayText" : "CCHT/HOME TELEHEALTH", "Text" : "Home Telehealth Consult"},
{"Row" : 39, "Column" : 1, "Item" : "CHF GMRCTZ WEIGHT MANAGEMENT OUTPATIENT CONSULT", "DisplayText" : "WEIGHT MANAGMENT OUTPATIENT CONSULT", "Text" : "Weight Management Consult Menu..."},
{"Row" : 40, "Column" : 1, "Item" : "DM GMRCZ NUTRITION DIABETES EDUCATION CONSULT OUTPATIENT", "DisplayText" : "NUTRITION DIABETES EDUCATION CONSULT OUTPATIENT", "Text" : "Nutritional Diabetes Consult"},
{"Row" : 35, "Column" : 2, "Text" : "Women should discontinue at least 2 months before planned pregnancy"}, 
{"Row" : 2, "Column" : 1, "Text" : "Use high glycemic variability (A1C fluctuation or fasting blood glucose) as a"}, 
{"Row" : 3, "Column" : 1, "Text" : "prognostic indicator for risk of hypoglycemia, morbidity, and mortality"}, 
{"Row" : 4, "Column" : 1, "Text" : "Select A1c Target Range based on risk-benefit ratio, patient characteristics/"}, 
{"Row" : 5, "Column" : 1, "Text" : "preference, complications/comorbidities/life expentancy (A1C range of 7-8.5%"}, 
{"Row" : 6, "Column" : 1, "Text" : "for most patients, when it can be safely obtained)"}, 
{"Row" : 12, "Column" : 1, "Text" : "(Weight (N), A1c dec. (-1.5))"}, 
{"Row" : 18, "Column" : 2, "Text" : "Preferred for HFpEF or HFmrEF"}, 
{"Row" : 22, "Column" : 3, "Text" : "AVOID in CHF and active Bladder Cancer patients"}, 
{"Row" : 24, "Column" : 3, "Text" : "May be helpful with NASH"}, 
{"Row" : 25, "Column" : 3, "Text" : "Baseline LFTs (Required)"}, 
{"Row" : 32, "Column" : 3, "Text" : "--Prioritize other classes of agents first, especially >= 65 yo"}, 
{"Row" : 32, "Column" : 2, "Text" : "Benefits in ASCVD, CKD (reduced albuminuria)"}, 
{"Row" : 31, "Column" : 2, "Text" : "Slows gastric emptying"}, 
{"Row" : 30, "Column" : 2, "Text" : "Semaglutide, Dulaglutide, Liraglutide (Weight (-), A1c dec. (-0.5 to -1.0))"}, 
{"Row" : 29, "Column" : 2, "Text" : "GLP-1 (Glucagon-like Peptide-1)", "Header" : 1}, 
{"Row" : 45, "Column" : 3, "Text" : "Insulin Treatment", "Header" : 1}, 
{"Row" : 46, "Column" : 3, "Text" : "Insulin Therapy (Weight (+), A1c dec.  (-1.5 to -2.5)"}, 
{"Row" : 15, "Column" : 3, "Text" : "Avoid if high risk of pancreatitis"}, 
{"Row" : 15, "Column" : 2, "Text" : "Preferred 2nd line per PBM"}, 
{"Row" : 47, "Column" : 3, "Text" : "Consider starting temporarily for new presentations of diabetes WITH GLUCOSE"}, 
{"Row" : 48, "Column" : 3, "Text" : "    TOXICITY (BGs>300, A1C>10, or polyuria/polydipsia/weight loss). Once glucose"}, 
{"Row" : 49, "Column" : 3, "Text" : "    toxicity resolves, simplify and switch to preferred non-insulin agents"}, 
{"Row" : 50, "Column" : 3, "Text" : "    when possible."}, 
{"Row" : 51, "Column" : 3, "Text" : "Preferred in pregnancy"}, 
{"Row" : 52, "Column" : 3, "Text" : "If significant variability or not achieving glycemic goals while on insulin"}, 
{"Row" : 53, "Column" : 3, "Text" : "    therapy, use real-time continuous glucose monitoring to decrease hyopglycemia"}, 
{"Row" : 54, "Column" : 3, "Text" : "    and improve HgA1C."}
]}
]
